PhotoCure - Underwritten rights offering
PhotoCure has established a consortium consisting of
| Gezina AS |
| Arendals Fossekompani ASA |
| Ferd AS |
| Radiumhospitalets Forskningstiftelse |
| Rustad AS |
| Vicama AS |
| Range Capital |
| Odin Norge |
| DNBNOR Kapitalforvaltning Fondene |
| Vital |
| Skagen Vekst 1 |
| Skagen Vekst 3 |
| Bergen Kommunale PK |
| Ragnhild Ulstein Loen |
| Miraa Verdi AS |
| Marlin Verdi AS |
| ELL Loen |
| Vikerud Verdi AS |
| Ingus Verdi AS |
| Mustad Industrier AS |
| Pumpøs AS |
| MP Pensjon |
| Fondsfinans Kapitalforvaltning |
| Waterman Holding Inc |
| Norsk Hydro PK |
who has underwritten a rights issue in the company of NOK 202 million with a subscription price of NOK 46 per share.
The Board of PhotoCure ASA has consequently resolved to convene an extraordinary general meeting of its shareholders with a proposal to resolve a rights issue to raise approx. NOK 202 million of equity capital by issuing 4.396.051 shares of par value NOK 0.50 each. The proposed subscription price is NOK 46 per share.
Shareholders will have a pre-emptive right to subscribe to shares in the issue. Four shares will give the right to subscribe one new share. Oversubscription will be allowed and subscription rights will be issued for trading. It is proposed that the subscription period will be from Friday 3 February 2006 to and including Friday 17 February 2006 at 16.00 (Norwegian time). Fondsfinans ASA will manage the rights issue.
"I am very pleased that existing and new shareholders have expressed this great interest in the future development of PhotoCure's new and innovative pharmaceutical products" says CEO Kjetil Hestdal. " I am very happy to notice the large oversubscription of the underwriting consortium".